Long-acting Mesalamine may effectively reduce symptoms in Postinfectious Irritable Bowel Syndrome: Study
A new study revealed that Mesalamine, an anti-inflammatory drug, can effectively treat postinfectious irritable bowel syndrome (PI-IBS) symptoms and improve the quality of life. The study results were published in the journal Neurogastroenterology & Motility.
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain and alteration in bowel frequency or consistency in the absence of a gross structural or biochemical abnormality. Postinfectious irritable bowel syndrome ((PI-IBS) is a condition associated with low-grade intestinal inflammation. It develops in a subset of patients after gastroenteritis. Previous studies showed that long-acting Mesalamine can be used to treat IBS. Hence, researchers conducted a study to investigate the efficacy of long-acting Mesalamine in individuals with PI-IBS particularly those with diarrhea-predominant IBS (IBS-D) following gastroenteritis, as PI-IBS is linked to low-grade intestinal inflammation.
A Randomized double-blind placebo-controlled study was carried out on a total of 61 patients who developed IBS-D after gastroenteritis. Individuals were randomly assigned to receive either 2.4 g of long-acting mesalamine or a placebo daily for 8 weeks. The study assessed symptoms including abdominal pain, bloating, stool frequency, stool consistency, severity of diarrhea and constipation, satisfaction with bowel habits, and how much IBS affected or interfered with life. Quality of life (QOL) was measured using the IBS-QOL questionnaire. The primary outcome was the overall bowel symptom score (BSS) after 8 weeks of treatment. Effect sizes were quantified using standardized mean differences (Cohen's d).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.